Last updated: May 28, 2026
Barium sulfate is supplied globally by multiple manufacturers in contrast-grade and compounding-ready forms for oral suspension and related radiology uses. No single supplier dominates across all dosage forms and markets. The supply chain is typically segmented by (1) finished product manufacturers for radiology, (2) API and high-purity barium sulfate producers for industrial and pharma use, and (3) contract manufacturers supplying oral suspension presentations under label/brand licenses.
Which companies supply barium sulfate for pharmaceutical and radiology use?
Short answer: Supply comes from finished-dose drug manufacturers and from barium sulfate producers that sell pharma-grade powders for suspension manufacture.
Finished product suppliers (oral contrast suspensions)
Finished barium sulfate oral suspensions are commonly marketed under national radiology brands and are produced by domestic and international pharmaceutical firms, including companies that also supply other imaging contrast agents and gastrointestinal imaging products.
Key supplier categories:
- Radiology-focused branded product manufacturers producing oral barium sulfate suspensions.
- Generic drug manufacturers producing barium sulfate suspensions under ANDA-marketed products where available by country.
- Contract development and manufacturing organizations (CDMOs) producing oral suspensions for branded or distributor labels.
Bulk barium sulfate (pharma-grade powder)
Bulk supply typically includes:
- Barium sulfate precipitation manufacturers producing high-purity grades for medical and pharmaceutical applications.
- Chemical producers that certify purity, particle size, and contaminant profiles (lead, arsenic, and other heavy metals) to pharma and regulatory specifications.
What barium sulfate grades are used in oral contrast products?
Short answer: Radiology products typically require controlled purity, particle size distribution, and low heavy metal content suitable for ingestion and imaging performance.
Common grade controls include:
- Purity and assay: meeting pharmacopeial or internal pharma specifications.
- Heavy metals: lead and other trace contaminants controlled by certification and testing.
- Particle size: affects suspension stability and imaging characteristics.
- Reproducible precipitation and washing: controls variability in residual soluble salts.
Who produces pharmaceutical-grade barium sulfate powder (API-equivalent) for suspension manufacture?
Short answer: Pharmaceutical barium sulfate powder is usually produced by specialized inorganic chemical suppliers using controlled precipitation, filtration, and washing steps.
Vetting points that matter for pharma use:
- Demonstrated consistency across lots for particle size and residual impurities.
- Documented analytical methods and batch release testing.
- Ability to provide regulatory documentation and quality agreements for compounding.
How do you vet barium sulfate suppliers for compliance, quality, and supply continuity?
Short answer: Use a standard vendor qualification process anchored on quality systems, pharmacopeial alignment, impurity controls, and delivery reliability.
Supplier qualification checklist (high-impact)
- Quality management system: GMP capability for finished products or quality system controls for bulk.
- Regulatory history: inspection outcomes and complaint trends for the supplier’s barium sulfate manufacturing site.
- Testing and specifications: heavy metals, assay, particle size, microbial controls if applicable.
- Stability and handling: filtration, drying, and packaging controls for suspension performance.
- Traceability: lot-level COAs, change control, and supplier documentation.
- Capacity and redundancy: ability to maintain supply in peak imaging demand cycles.
What documentation should barium sulfate suppliers provide to pharma buyers?
Short answer: Buyers typically require COAs, specifications, and regulatory-quality documentation appropriate to the intended use (finished drug vs compounding bulk).
Documents commonly requested:
- Certificate of Analysis (COA) per lot
- Specification sheet aligned to pharmacopeial or customer requirements
- Manufacturing and quality documentation: GMP certificate for drug sites or quality system documentation for bulk
- Impurity and heavy metal reports (lead and other trace elements)
- Stability data where applicable (especially for finished suspensions)
- Change history and deviation/CAPA summaries on recent process changes
Are there supplier concentration risks in barium sulfate?
Short answer: Yes, concentration risk exists at the site level because precipitation, purification, and drying steps are specialized and can be capacity constrained, especially when a small number of sites support high-purity pharma grades.
Risk factors:
- Single-site dependency for a pharma-qualified grade
- Capacity bottlenecks in purification or drying trains
- Broad chemical use competing for the same raw materials
- Regulatory-quality constraints that reduce the pool of qualified suppliers
How does barium sulfate supplier selection differ by market (US, EU, other regions)?
Short answer: Supply structure varies by market based on whether buyers source finished radiology product or compounding bulk and on how local regulatory listings are handled.
Market-specific impacts:
- US: sourcing often uses finished-dose suppliers and distributors backed by FDA/Orange Book listings where applicable, or bulk purchase for compounding where permitted.
- EU: product availability depends on EMA frameworks and national marketing authorizations; bulk supply still requires compliance with GMP where applicable.
- Other regions: local availability and labeling norms influence whether international suppliers sell finished units or only bulk.
What supply model is most common: finished drug vs bulk compounding?
Short answer: Hospitals and radiology centers typically use finished products. Pharmacies and specialty compounding workflows depend on local rules and rely on bulk supply only when permitted.
Selection drivers:
- Regulatory and labeling requirements
- Shelf-life and stability for suspension use
- Consistency of suspension performance
- Ability to meet quality systems for compounding
What are common failure points with barium sulfate supply?
Short answer: The most common issues are batch-to-batch variability in powder properties, instability of suspensions, and impurity excursions.
Top failure modes:
- Suspension instability: settling, caking, or viscosity drift caused by particle size variability.
- Heavy metal/impurity excursions: precipitation or washing variability.
- Change-control gaps: formulation or processing changes that alter performance.
- Packaging and moisture sensitivity: changes in moisture uptake affecting dispersibility.
Key Takeaways
- Barium sulfate supply is split between finished radiology products and bulk pharma-grade powder supplied for suspension manufacture or compounding.
- Supplier qualification hinges on purity/impurity controls, particle size consistency, and quality-system evidence.
- Supply risk is usually site- and grade-specific, not just company-specific, so qualification should focus on manufacturing trains and batch release reliability.
FAQs
- What purity and heavy metal limits matter most for barium sulfate used in oral contrast?
- How does particle size affect barium sulfate suspension stability and imaging performance?
- What documentation do buyers need from barium sulfate suppliers for GMP-aligned purchasing?
- Is it safer for hospitals to source finished barium sulfate suspensions rather than bulk powder?
- What are the main quality deviation drivers in barium sulfate precipitation and purification?
References
- United States Pharmacopeia (USP). USP Monographs: Barium Sulfate (current edition).
- European Pharmacopoeia (Ph. Eur.). Barium Sulfate monograph (current edition).
- U.S. FDA. Current Good Manufacturing Practice (CGMP) regulations and guidance for drug manufacturing (current).
